|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
1995-10-4
|
|
pubmed:abstractText |
The success of tamoxifen in reducing the occurrence of contralateral breast cancer among breast cancer patients in clinical trials has prompted the study of its use in the primary prevention of breast cancer. Long-term risks associated with tamoxifen therapy, however, are still being evaluated, particularly with respect to subsequent cancer occurrence at sites other than the breast.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1359-64
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7658496-Adult,
pubmed-meshheading:7658496-Aged,
pubmed-meshheading:7658496-Aged, 80 and over,
pubmed-meshheading:7658496-Breast Neoplasms,
pubmed-meshheading:7658496-Case-Control Studies,
pubmed-meshheading:7658496-Endometrial Neoplasms,
pubmed-meshheading:7658496-Female,
pubmed-meshheading:7658496-Humans,
pubmed-meshheading:7658496-Middle Aged,
pubmed-meshheading:7658496-Neoplasms, Second Primary,
pubmed-meshheading:7658496-Ovarian Neoplasms,
pubmed-meshheading:7658496-Population Surveillance,
pubmed-meshheading:7658496-Tamoxifen,
pubmed-meshheading:7658496-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.
|
|
pubmed:affiliation |
Department of Epidemiology, University of Washington, Seattle, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
